Flputnam Investment Management Co. Buys 4,293 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Flputnam Investment Management Co. increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,768 shares of the medical research company's stock after acquiring an additional 4,293 shares during the period. Flputnam Investment Management Co. owned about 0.12% of Charles River Laboratories International worth $14,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. VisionPoint Advisory Group LLC grew its position in Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth about $37,000. Operose Advisors LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth about $42,000. Covestor Ltd grew its position in Charles River Laboratories International by 100.0% in the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company's stock worth $49,000 after purchasing an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its position in Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock worth $51,000 after purchasing an additional 112 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Citigroup upped their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research report on Friday, March 1st. Evercore ISI increased their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an "outperform" rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their target price on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Finally, UBS Group increased their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of "Moderate Buy" and an average target price of $253.23.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

NYSE CRL traded down $5.41 on Monday, hitting $235.93. The stock had a trading volume of 455,432 shares, compared to its average volume of 552,043. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The company has a market capitalization of $12.15 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 1.89 and a beta of 1.40. The firm has a 50-day moving average of $253.00 and a 200-day moving average of $220.60.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business's quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the company posted $2.98 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).